1. A method for preparing a building material, comprising:
mixing an aggregate material, water, a hydraulic binder material, and one or more hydraulic activators; and
allowing the building material to harden;
wherein the hydraulic binder material comprises slag material.
2. The method of claim 1, wherein the slag material is ground to a specific area of approximately 3000-5000 cm2g.
3. The method of claim 1, wherein the slag material is ground to a specific area of approximately 3500 cm2g.
4. The method of claim 1, wherein the slag material includes CaO and SiO2, and the ratio CaOSiO2 ranges from 0.25-2.0.
5. The method of claim 1, wherein the slag material includes Al2O3 and SiO2, and the ratio Al2O3SiO2 ranges from 0.1-0.6.
6. The method of claim 1, wherein the slag material is ground granulated blast furnace slag.
7. The method of 6, wherein the slag material is an amorphous ground granulated blast furnace slag material.
8. The method of claim 1, wherein the one or more hydraulic activators are alkaline activators.
9. The method of claim 8, wherein the activators comprise alkali metals andor solutions thereof.
10. The method of claim 9, wherein the activators comprise hydroxides, silicates andor carbonates of the alkali metals andor solutions thereof.
11. The method of claim 8, wherein the activators comprise a mixture of sodium hydroxide, waterglass and sodium metasilicate.
12. The method of claim 1, further comprising adding one or more additives to the aggregate material, water, hydraulic binder material, and one or more hydraulic activators, before or during mixing.
13. The method of claim 12, wherein an additive comprises bivalent iron.
14. The method of claim 12, wherein an additive comprises potassium dichromate.
15. A building material prepared by the method of claim 1.
16. A composition, comprising:
a slag material, and
one or more hydraulic activators.
17. The composition of claim 16, wherein the slag material is ground to a specific area of approximately 3000-5000 cm2g.
18. The composition of claim 17, wherein the slag material is ground to a specific area of approximately 3500 cm2g.
19. The composition of claim 16, wherein the slag material consists of neutral or alkaline slags.
20. The composition of claim 16, wherein the slag material further comprises CaO and SiO2 in a ratio of 0.25:1 to 2.0:1.
21. The composition of claim 16, wherein the slag material further comprises Al2O3 and SiO2 in a ratio of 0.1:1 to 0.6:1.
22. The composition of claim 16, wherein the slag material is ground granulated blast furnace slag.
23. The composition of 22, wherein the slag material is an amorphous ground granulated blast furnace slag material.
24. The composition of claim 16, wherein the activators comprise alkaline activators.
25. The composition of claim 24, wherein the activators comprise alkali metals andor solutions thereof.
26. The composition of claim 25, wherein the activators comprise hydroxides, silicates andor carbonates of the alkali metals andor solutions thereof.
27. The composition of claim 24, wherein the activators comprise a mixture of sodium hydroxide, waterglass and sodium metasilicate.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for reducing temozolomide-resistance of brain cancer cells in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I), a pharmaceutically acceptable salt of (Z)-butylidenephthalide, a pharmaceutically acceptable ester of (Z)-butylidenephthalide, and combinations thereof:
2. The method as claimed in claim 1, wherein the active ingredient is (Z)-butylidenephthalide.
3. The method as claimed in claim 1, wherein the brain cancer cells are human malignant glioma cells.
4. The method as claimed in claim 1, which is used for increasing the cytotoxic sensitivity of temozolomide to temozolomide-resistant brain cancer cells.
5. A method for treating brain cancer in a subject, comprising administrating to the subject an effective amount of an active ingredient selected from the group consisting of (Z)-butylidenephthalide of formula (I), a pharmaceutically acceptable salt of (Z)-butylidenephthalide, a pharmaceutically acceptable ester of (Z)-butylidenephthalide, a pharmaceutically acceptable ester of (Z)-butylidenephthalide, and combinations thereof:
6. The method as claimed in claim 5, wherein the active ingredient is (Z)-butylidenephthalide.
7. The method as claimed in claim 5, wherein the brain cancer is human malignant glioma.
8. The method as claimed in claim 5, further comprising administrating to the subject an effective amount of an anti-cancer component selected from the group consisting of temozolomide, a hydrate of temozolomide, an isostere of temozolomide, a pharmaceutically acceptable salt of temozolomide, and combinations thereof.
9. The method as claimed in claim 8, wherein the anti-cancer component is temozolomide.
10. The method as claimed in claim 9, wherein the active ingredient is (Z)-butylidenephthalide.
11. The method as claimed in claim 10, wherein temozolomide and (Z)-butylidenephthalide together provide a combination index less than 1.
12. The method as claimed in claim 10, wherein (Z)-butylidenephthalide is administrated in form of a wafer at a daily dosage of about 30 mgkg-body weight to about 500 mgkg-body weight, and temozolomide is administered as a wafer at a daily dosage of about 10 mgkg-body weight to about 100 mgkg-body weight.
13. The method as claimed in claim 12, wherein (Z)-butylidenephthalide is administered at a daily dosage of about 40 mgkg-body weight to about 120 mgkg-body weight, and temozolomide is administrated at a daily dosage of about 40 mgkg-body weight to about 80 mgkg-body weight.
14. The method as claimed in claim 8, wherein the active ingredient and the anti-cancer component are administered together, separately, or successively.
15. The method as claimed in claim 10, wherein (Z)-butylidenephthalide is administered orally or administered by subcutaneous or intravenous injection and temozolomide is administered orally.